Do probiotics work for IBS?
Possibly, for some people, but the evidence is weaker than the packaging suggests. Pooled trial data lean slightly positive, while the quality of that data is the problem.
The most recent large pooled analysis from the group that has tracked this question for years pulled together 82 randomized trials with 10,332 adults, comparing probiotics with placebo. Only 24 trials were at low risk of bias across all domains. Some strains or combinations looked beneficial, but the certainty of the evidence by the GRADE system was moderate for Escherichia strains on global symptoms and low to very low for nearly everything else. The authors' conclusion was that some combinations or strains may be beneficial, with low to very low certainty across almost all analyzes (Goodoory 2023). A 2026 update of the pooled evidence, covering 40 studies, again found a significant improvement in IBS symptom severity scores, and its authors called for larger, standardized trials and better handling of the differences between studies (Tang 2026).
The older headline figure is easy to find. A 2014 review of 43 trials reported that the relative risk of IBS symptoms persisting with probiotics versus placebo was 0.79 (95% CI 0.70 to 0.89), and it concluded that probiotics seemed effective, while noting that which strains work best was unclear (Ford 2014). Read that carefully. A relative risk of 0.79 means that people on probiotics were somewhat less likely to remain symptomatic than people on placebo. It does not mean most people respond, and it does not tell you about any particular product.
Two features of IBS make this evidence tricky to read. First, IBS symptoms wax and wane on their own, so people often start a new product when they feel at their worst and then feel better with or without it. Second, placebo response is large. A meta-analysis of trials in IBS found that about 37.5% of people on placebo reported improvement, with higher rates in trials that were shorter or used physician-reported outcomes (Ford 2010). That analysis covered drug trials, not probiotic trials specifically, so treat the number as a sense of scale rather than a probiotic benchmark. The practical consequence is that "I felt better after a few weeks on a probiotic" is a real experience that cannot, by itself, tell you the probiotic did it.
People in the community describe this ambivalence themselves. In r/ibs, a highly upvoted thread titled "Probiotics changed my life" sits alongside a long thread asking whether probiotics have cured anyone's IBS and several threads asking whether probiotics are making things worse. I am not treating any of that as evidence about whether probiotics work. It does show that real experience runs in both directions, which is exactly what you would expect if the average effect is small and varies by person and product.
What do the guidelines say about probiotics for IBS?
The three major guidelines reach three different conclusions: suggest against (ACG), no recommendation (AGA), and a time-limited trial is reasonable (UK's BSG). They are all looking at overlapping evidence, and the differences come from how they group it and how cautious they are about its quality.
| Guideline | Year | What it says about probiotics in IBS | Strength and evidence quality |
|---|---|---|---|
| American College of Gastroenterology (ACG) | 2021 | Suggests against probiotics for the treatment of global IBS symptoms. | Conditional, very low quality evidence |
| American Gastroenterological Association (AGA) | 2020 | Makes no recommendation for probiotics in adults and children with IBS. | Not applicable (no recommendation) |
| British Society of Gastroenterology (BSG) | 2021 | Probiotics as a group may be effective for global symptoms and abdominal pain, but a specific species or strain cannot be recommended. Reasonable to advise those wishing to try them to take them for up to 12 weeks and discontinue if no symptom improvement. | Weak, very low quality evidence |
The BSG wording comes from its guideline, which pooled 45 trials and found significant effects on global symptoms or abdominal pain for combinations of probiotics (relative risk 0.79), Lactobacillus (0.75), Bifidobacterium (0.80) and Escherichia (0.86), with adverse events similar to placebo (Vasant 2021). Its panel called the recommendation weak, based on very low quality evidence.
The ACG reached the opposite practical conclusion from a similar pool of data. It described the literature as small studies, multiple types and strains of probiotics, inconsistent effects on individual symptoms and a lack of trials built on the endpoints regulators use for drugs. It also noted that in the pooled data no category of probiotic had shown a significant benefit for bloating (Lacy 2021).
The AGA guideline is the odd one out because it judged each probiotic formulation separately rather than lumping them together. AGA's own media briefing explains that this is why it reached a different conclusion from earlier society documents: it makes no recommendation for IBS, citing a lack of evidence, and it pointed to the associated costs and the lack of enough evidence to show the products are free of harm (Su 2020). To be clear about what I could and could not confirm: I read the AGA's published media briefing on its guideline, but the full guideline text was behind a publisher paywall, so I am reporting the "no recommendation" position as the AGA itself summarized it.
So when someone says "the guidelines say" probiotics work, or do not work, ask which guideline. The honest summary is that expert groups looked at the same weak evidence and drew different lines, and that none of them endorses a particular product.
Which probiotic strains have been studied for IBS?
Several strains have positive trials, a few have mixed or negative ones, and the certainty is low across the board. The key lesson is that probiotics are not interchangeable: results belong to a named strain, in a named dose and formulation, tested in a named population.
A 2026 strain-specific meta-analysis restricted itself to randomized placebo-controlled trials of single-strain products. It included 32 articles covering 10 strains. Its findings, as the authors summarized them:
- Benefit on key IBS symptoms for Bifidobacterium longum 35624 (formerly called Bifidobacterium infantis), Lactobacillus rhamnosus GG, Lactiplantibacillus plantarum 299v, Saccharomyces cerevisiae CNCM I-3856 and Bacillus coagulans Unique IS2.
- Improved quality of life, but not the other measures, for Bacillus coagulans MTCC 5856.
- Conflicting results for Saccharomyces boulardii CNCM I-745.
- No demonstrated efficacy for Escherichia coli Nissle 1917, Lactobacillus gasseri BNR17 or Lactobacillus casei Shirota (Maslennikov 2026).
The 2023 meta-analysis grouped things differently, by genus and named formula. It found moderate-certainty evidence for a benefit of Escherichia strains on global symptoms, low-certainty evidence for Lactobacillus strains and L. plantarum 299v, and low-certainty evidence for Saccharomyces cerevisiae I-3856 and Bifidobacterium strains on abdominal pain. Combination probiotics and Bacillus strains had only very low certainty (Goodoory 2023). Notice that the two reviews do not line up neatly: one says E. coli Nissle 1917 did not show benefit, the other found moderate-certainty benefit for "Escherichia strains" as a group. Different inclusion rules and groupings produce different verdicts, which is itself a sign of how unsettled this is.
What the individual trials look like
Looking at a few of the best-known single-strain trials shows why guidelines are cautious.
Bifidobacterium longum 35624. A multicenter trial in 362 women with IBS in primary care tested three strengths against placebo for 4 weeks. Only one of the three strengths beat placebo on the primary outcome of abdominal pain, and the investigators reported improvement in global symptom assessment exceeding placebo by more than 20% in that arm (Whorwell 2006). The ACG pointed out that the lack of a dose-response was hard to explain (Lacy 2021). It was a four-week trial in women only.
Lactiplantibacillus plantarum 299v. A 4-week double-blind placebo-controlled trial of 214 adults meeting Rome III criteria found that pain severity and bloating improved more with the strain than with placebo (Ducrotte 2012). The study was industry-supported, a point worth knowing, and four weeks says nothing about months of use.
Saccharomyces cerevisiae CNCM I-3856. A 12-week trial of 379 people found no overall benefit in the whole IBS group on its primary outcome, yet a planned subgroup analysis suggested improvement in abdominal pain and bloating in people with predominantly constipated IBS (Spiller 2016). The ACG noted that 32.2% of treated people and 26.9% on placebo were responders, a difference that was not statistically significant. Subgroup findings can be real, but they are best treated as a lead for the next trial, not a conclusion.
The pattern is common: a positive result in a particular subgroup, a trial that is shorter than most people's real-life experience, a manufacturer involved in the study, and a primary outcome that was not met. Nothing here makes those strains useless. It does mean "clinically proven" on a label should prompt the question "proven in what, for how long, and compared with what?"
How long should a probiotic trial last?
The only guideline wording on this comes from the BSG: up to 12 weeks, then stop if symptoms have not improved. That is a quote of a guideline statement, not personal advice.
The BSG says it is "reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, and to discontinue them if there is no improvement in symptoms", and rated that recommendation weak with very low quality evidence (Vasant 2021). The trial lengths in the research tell a similar story about timescale: the 2006 B. longum 35624 trial ran 4 weeks (Whorwell 2006), the 2012 L. plantarum 299v trial ran 4 weeks (Ducrotte 2012) and the 2016 S. cerevisiae trial ran 12 weeks (Spiller 2016).
A few honest points follow from that, none of which is instruction.
- Judging a trial is hard without a baseline. The BSG's "if there is no improvement" assumes you can tell. With IBS, which fluctuates, that takes a record of how you were before, not a memory of it. Our guide to how to keep a food diary for IBS covers what to write down.
- A new product and a new diet change are not the same experiment. If you add a probiotic during a flare, a diet change or a stressful month, you cannot tell which thing moved your symptoms. Our guide to how to calm an IBS flare-up covers what is worth doing during a flare, and nothing in it depends on a supplement.
- Tell the people supervising your care. Particularly your dietitian, if you are working through a low FODMAP process, because probiotic products can contain added fibers that complicate reintroduction. For that process, see how to reintroduce foods after the low FODMAP diet.
A fair summary of the "how long" question is that the research offers 4 to 12 weeks as the span in which trials looked for an effect, and one guideline treats up to 12 weeks as a reasonable limit. Nobody has shown that longer is better.
Can probiotics make IBS worse?
For some people, yes, and a bad reaction is a reason to speak to a clinician rather than push through. In pooled trials, adverse events were not significantly more common with probiotics than with placebo, but that average hides individual differences.
The 2023 meta-analysis analyzed adverse events in 55 trials involving more than 7,000 people and found no significantly higher risk of any adverse event with probiotics (Goodoory 2023), and the BSG reported similar adverse event rates in probiotic and placebo arms (Vasant 2021). Yet the ACG highlighted a large blinded probiotic study, though not in IBS, in which a product containing Lactobacillus acidophilus and Bifidobacterium bifidum was associated with bloating in the treated group (Lacy 2021). The AGA, as summarized above, also noted that there is not enough evidence to be sure the products carry no harm (Su 2020).
People in r/ibs ask this question constantly. Threads include asking how long to feel worse before feeling better, whether it only gets worse at first, and describing bloating or constipation after starting one. The common theme is uncertainty about whether to push on or stop. That is a reasonable thing to ask a pharmacist or doctor, and no forum can answer it for you. I could not find a controlled study showing that early worsening predicts later benefit, so I would not repeat the "it gets worse before it gets better" idea as fact.
One unusual finding deserves a careful mention because it concerns people with bloating specifically. A 2018 clinic series described 30 patients with gas, bloating and "brain fogginess" who all used probiotics; many had small intestinal bacterial overgrowth (SIBO) and signs of D-lactic acidosis. Symptoms improved in 23 of 30 after probiotics were stopped and a course of antibiotics was given (Rao 2018). It was a small series from a single specialist center, with no control group and a population selected for odd symptoms, so it cannot tell us how common this is or whether probiotics caused it. I mention it so that someone who develops mental fog along with worsening bloating knows it is worth raising with a doctor rather than putting up with. For how SIBO and IBS overlap and differ, see SIBO vs IBS symptoms.
When to see a doctor promptly
Probiotics are not a reason to delay getting checked. See a doctor promptly if you have any of these, whatever supplements you are taking: blood in your stool, black or tarry stools, unexplained weight loss, fever, night-time symptoms that wake you, signs of anemia, symptoms that began after age 50, or a family history of bowel cancer or inflammatory bowel disease. IBS is a diagnosis made after other conditions are considered, and these features need investigating, not supplementing.
If you also have SIBO, the picture differs: can SIBO be treated without antibiotics covers the pooled probiotic data and the D-lactic acidosis case series.
Probiotics vs fermented foods
They are not the same thing, and the evidence for fermented foods is also small and cautious. An international expert panel defined fermented foods as "foods made through desired microbial growth and enzymatic conversions of food components", and separated them from probiotics, which need to be defined strains given in adequate amounts with a demonstrated health benefit (Marco 2021). Many fermented foods contain live microbes, but that does not make them probiotics in the formal sense. Sourdough bread, for example, is fermented but the microbes are killed in baking.
What do trials show? A 2024 meta-analysis of 16 randomized trials with 1,264 people with IBS found that fermented foods were associated with more symptom relief (relative risk 1.22, 95% CI 1.04 to 1.42) and a small improvement in global symptom scores, but no significant improvement in abdominal pain or bloating scores. A subgroup analysis suggested that fermented milk had a beneficial effect. The authors described the conclusion as one to interpret with caution given the limits of the evidence (Ding 2024). Notice that many of the "fermented foods" in those trials were dairy products with added probiotic strains, so the result blends two categories.
A few practical considerations follow, framed as things to know rather than things to do.
- Fermented foods can contain FODMAPs. Some fermented foods are high in lactose, fructans or other fermentable carbohydrates, which may be exactly what a person is trying to reduce. Kefir and yogurt contain lactose in varying amounts, and sauerkraut and kimchi often contain onion or garlic. For how those carbohydrates behave, see do FODMAP enzymes work, which sets out the subgroups.
- Foods bring other things with them. A bowl of yogurt is also dairy, fat and sugar, and a fermented drink may contain alcohol, caffeine or added sweeteners. Each of those can matter on its own for IBS.
- Food tolerance is individual. Some people tolerate a spoonful of a fermented food and others do not, which is why a record of what you ate and how you felt over the next hours and days beats a general rule.
There is also a gap in the evidence worth stating plainly: I did not find a trial comparing fermented foods head to head with a defined probiotic product in IBS, so "which is better" is unanswered.
Are probiotics worth the money?
It depends on what you are paying for, and the evidence cannot make that call for you. Here is what we can say without guessing prices: the pooled evidence is real but low in certainty, the effects found are modest, and guidelines disagree on whether trying one is sensible.
The AGA explicitly cited cost as one reason for its position, alongside the absence of enough evidence to rule out harm (Su 2020). The ACG called the existing studies small and not rigorous by the standards applied to drugs (Lacy 2021). The BSG's position was that for people who want to try one, a limited trial is reasonable (Vasant 2021). Three expert groups, three framings of the same uncertainty.
A more intensive microbiome approach, fecal transplant, is still experimental for IBS and SIBO; see can a fecal transplant cure SIBO for what the trials show and the risks of doing it outside research.
Some questions help you think about value without anyone telling you what to do.
- Is the product one with published trials in IBS? Many products on sale have trials on a different strain or no IBS trials at all. The strain and the trial population need to match.
- What would count as success for you? Fewer bloating days, a more regular stool pattern, less pain. Decide before starting, because the placebo effect in IBS is large and a vague goal is easy to meet by accident.
- What else is changing at the same time? If the answer is "a lot", any result is hard to interpret and the money is better spent elsewhere, such as on seeing a dietitian.
- Are you taking any medicines or do you have another condition? A pharmacist or doctor is the person to ask, particularly if you are immunosuppressed.
Dietitian-led approaches have much stronger evidence in IBS than probiotics. The low FODMAP diet, done as a short structured process with reintroduction, is the dietary approach recommended by the ACG as a limited trial, and for many people that is a better use of limited time and money than a shelf of supplements (Lacy 2021).
How to test a probiotic fairly if you decide to try one
This section is about method, not about whether to try one. If you and your clinician decide a time-limited trial is reasonable, a few habits make the result easier to read. None of them involves a product or amount.
- Get a baseline first. Two to four weeks of records before you start: stool type, pain, bloating, urgency, and what you ate. Memory flatters bad weeks and ignores good ones.
- Change one thing at a time. Leave diet, other supplements and medicines alone as far as you can, and tell your clinician what you are taking.
- Write down the end date in advance. The BSG's 12-week ceiling is a guideline statement. Whatever period you and your clinician agree, set it before you start so you are not drifting.
- Judge by your own measures. Pick the two or three symptoms that matter most to you and compare the final weeks of the trial with the baseline, not with your worst day.
- Remember normal variation. IBS fluctuates, so a single good week proves little. Several weeks of difference mean more.
Clairop, a free-to-download iPhone app (using it needs a Clairop Pro subscription), can hold that baseline: it logs meals by tap, voice, a typed sentence or a photo, one-tap Bristol stool entries with blood, mucus, urgency and night-time detail, and symptoms, and it can produce a one-page report for a GI visit labeled as patient-entered data. It is not a medical device, not clinically validated and not diagnostic, and it does not test probiotics as such; see how it works and method.
Clairop logs meals, symptoms and stool in seconds, then looks for the foods your gut reacts to, including reactions that land days later.
Myths about probiotics and IBS
A few ideas are repeated so often that they are worth checking against the research.
- "All probiotics do the same thing." They do not. Effects are strain-specific, and the strain-level reviews show some with benefit, some with conflicting results and some with none (Maslennikov 2026).
- "Guidelines recommend probiotics for IBS." One does, weakly, with a time limit. One suggests against, and one makes no recommendation. See the table above.
- "More colony-forming units is better." The B. longum 35624 trial tested three strengths and only one beat placebo, which is not a pattern of more equals better (Whorwell 2006).
- "Probiotics rebuild a damaged gut flora." The IBS trials measured symptoms, not microbiome repair. If you are curious about what stool microbiome tests can and cannot tell you, see are gut microbiome tests worth it.
- "If it did not work, I did it wrong." Many trials show no overall benefit. A negative result for you is an ordinary outcome, not a failure of effort.
- "Natural means harmless." Pooled trials found adverse events no more common than placebo, but individual reactions occur, and a few unusual syndromes have been described (Rao 2018).
- "Probiotics can cure IBS." Nothing in the research supports cure language. The best-case finding is modest symptom improvement in some people.
What to take to your appointment
If you are considering a probiotic, or already using one, these are useful things to bring to a doctor, dietitian or pharmacist.
- The product name and strain designations from the label, which a pharmacist can help interpret.
- How long you have used it, and what your symptoms were before.
- A few weeks of stool, symptom and food records.
- Any other supplements and medicines.
- Your specific question, such as "is there a reason for me not to try this?" or "does this interact with what I take?"
Frequently asked questions
The questions people ask most are answered in the FAQ below, each in a few sentences so you can find the answer fast. Nothing in this article is medical advice, and it is not a substitute for your own clinician, who knows your history and can examine you.




